Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-12

AUTHORS

Amalendu P Ranjan, Anindita Mukerjee, Lawrence Helson, Jamboor K Vishwanatha

ABSTRACT

BACKGROUND: Cardiac toxicity is the foremost reason for drug discontinuation from development to clinical evaluation and post market surveillance [Fung 35:293-317, 2001; Piccini 158:317-326 2009]. The Food and Drug Administration (FDA) has rejected many potential pharmaceutical agents due to QT prolongation effects. Since drug development and FDA approval takes an enormous amount of time, money and effort with high failure rates, there is an increased focus on rescuing drugs that cause QT prolongation. If these otherwise safe and potent drugs were formulated in a unique way so as to mitigate the QT prolongation associated with them, these potent drugs may get FDA approval for clinical use. Rescuing these compounds not only benefit the patients who need them but also require much less time and money thus leading to faster clinical translation. In this study, we chose curcumin as our drug of choice since it has been shown to posses anti-tumor properties against various cancers with limited toxicity. The major limitations with this pharmacologically active drug are (a) its ability to prolong QT by inhibiting the hERG channel and (b) its low bioavailability. In our previous studies, we found that lipids have protective actions against hERG channel inhibition and therefore QT prolongation. RESULTS: Results of the manual patch clamp assay of HEK 293 cells clearly illustrated that our hybrid nanocurcumin formulation prevented the curcumin induced inhibition of hERG K+ channel at concentrations higher than the therapeutic concentrations of curcumin. Comparing the percent inhibition, the hybrid nanocurcumin limited inhibition to 24.8% at a high curcumin equivalent concentration of 18 μM. Liposomal curcumin could only decrease this inhibition upto 30% only at lower curcumin concentration of 6 μM but not at 18 μM concentration. CONCLUSIONS: Here we show a curcumin encapsulated lipopolymeric hybrid nanoparticle formulation which could protect against QT prolongation and also render increased bioavailability and stability thereby overcoming the limitations associated with curcumin. More... »

PAGES

40

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1477-3155-11-40

DOI

http://dx.doi.org/10.1186/1477-3155-11-40

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024171001

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24330336


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Arrhythmia Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Phytogenic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Curcumin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ERG1 Potassium Channel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ether-A-Go-Go Potassium Channels", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HEK293 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ion Channel Gating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liposomes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Potentials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patch-Clamp Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Translational Medical Research", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of North Texas Health Science Center", 
          "id": "https://www.grid.ac/institutes/grid.266871.c", 
          "name": [
            "Department of Molecular Biology & Immunology and Institute for Cancer Research, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, 76107, Fort Worth, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ranjan", 
        "givenName": "Amalendu P", 
        "id": "sg:person.0702554625.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702554625.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Texas Health Science Center", 
          "id": "https://www.grid.ac/institutes/grid.266871.c", 
          "name": [
            "Department of Molecular Biology & Immunology and Institute for Cancer Research, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, 76107, Fort Worth, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukerjee", 
        "givenName": "Anindita", 
        "id": "sg:person.01203736343.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203736343.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "SignPath Pharmaceuticals, Pennsylvania, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Helson", 
        "givenName": "Lawrence", 
        "id": "sg:person.0671324400.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671324400.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Texas Health Science Center", 
          "id": "https://www.grid.ac/institutes/grid.266871.c", 
          "name": [
            "Department of Molecular Biology & Immunology and Institute for Cancer Research, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, 76107, Fort Worth, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vishwanatha", 
        "givenName": "Jamboor K", 
        "id": "sg:person.0747516710.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747516710.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.ahj.2009.06.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000865834"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2010.286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001165346", 
          "https://doi.org/10.1038/clpt.2010.286"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1088/0957-4484/22/29/295104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004077122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq295", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009767087"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq295", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009767087"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-3155-10-38", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014874253", 
          "https://doi.org/10.1186/1477-3155-10-38"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajpheart.00511.2012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025168883"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/009286150103500134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026019679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/009286150103500134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026019679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0735-1097(95)00424-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029484792"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.6925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029954603"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pcad.2010.05.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034614849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/prot.21400", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034736497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.31.12.1897", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036116109"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pbiomolbio.2008.10.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036351969"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bcp.12082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037191447"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.toxlet.2011.11.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042447511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/jrlcr.s37138", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046438963"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077974252", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-12", 
    "datePublishedReg": "2013-12-01", 
    "description": "BACKGROUND: Cardiac toxicity is the foremost reason for drug discontinuation from development to clinical evaluation and post market surveillance [Fung 35:293-317, 2001; Piccini 158:317-326 2009]. The Food and Drug Administration (FDA) has rejected many potential pharmaceutical agents due to QT prolongation effects. Since drug development and FDA approval takes an enormous amount of time, money and effort with high failure rates, there is an increased focus on rescuing drugs that cause QT prolongation. If these otherwise safe and potent drugs were formulated in a unique way so as to mitigate the QT prolongation associated with them, these potent drugs may get FDA approval for clinical use. Rescuing these compounds not only benefit the patients who need them but also require much less time and money thus leading to faster clinical translation. In this study, we chose curcumin as our drug of choice since it has been shown to posses anti-tumor properties against various cancers with limited toxicity. The major limitations with this pharmacologically active drug are (a) its ability to prolong QT by inhibiting the hERG channel and (b) its low bioavailability. In our previous studies, we found that lipids have protective actions against hERG channel inhibition and therefore QT prolongation.\nRESULTS: Results of the manual patch clamp assay of HEK 293 cells clearly illustrated that our hybrid nanocurcumin formulation prevented the curcumin induced inhibition of hERG K+ channel at concentrations higher than the therapeutic concentrations of curcumin. Comparing the percent inhibition, the hybrid nanocurcumin limited inhibition to 24.8% at a high curcumin equivalent concentration of 18\u00a0\u03bcM. Liposomal curcumin could only decrease this inhibition upto 30% only at lower curcumin concentration of 6\u00a0\u03bcM but not at 18\u00a0\u03bcM concentration.\nCONCLUSIONS: Here we show a curcumin encapsulated lipopolymeric hybrid nanoparticle formulation which could protect against QT prolongation and also render increased bioavailability and stability thereby overcoming the limitations associated with curcumin.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1477-3155-11-40", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031280", 
        "issn": [
          "1477-3155"
        ], 
        "name": "Journal of Nanobiotechnology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "name": "Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation", 
    "pagination": "40", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "73273d75620d24914d1a8069d9b837502aeda4c0b78ce000d73081b7bb92663e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24330336"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101152208"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1477-3155-11-40"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024171001"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1477-3155-11-40", 
      "https://app.dimensions.ai/details/publication/pub.1024171001"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000536.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1477-3155-11-40"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-3155-11-40'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-3155-11-40'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-3155-11-40'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-3155-11-40'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      21 PREDICATES      61 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1477-3155-11-40 schema:about N06ad92d30b414dacbb196e72d2b18e0a
2 N19c4e192cf0e49d59253614db0ec583b
3 N1f2d4d0dab0f47128de200cf41bab316
4 N244b3ade743c46e89a06af5bea897514
5 N2f808023e7f9444192ca40cda7e1a6f8
6 N32c8d3c9e6e74a2cac063e7664947957
7 N47712c3670f44ae585b3e7aecc074828
8 N5fa6ba0fbc494508bd110ac4f1595839
9 N632b924eb2f449d4a63ae7bf84bf2103
10 N8e5882437694465fbfe18d1c8f1f5048
11 N91f7f175eb6b41f2b21d34412b5efb8f
12 N96c374f0040346d1a703a2f8700434ec
13 Na772e020e76e407890302fad2a9d5f63
14 Nc10c75a15d5040348e5088dd2085477c
15 Nc645e0367b0f449990a4fea9ee58b74b
16 anzsrc-for:11
17 anzsrc-for:1115
18 schema:author N8b6cfd491ad34441b47c958d48eac9ea
19 schema:citation sg:pub.10.1038/clpt.2010.286
20 sg:pub.10.1186/1477-3155-10-38
21 https://app.dimensions.ai/details/publication/pub.1077974252
22 https://doi.org/10.1002/prot.21400
23 https://doi.org/10.1016/0735-1097(95)00424-6
24 https://doi.org/10.1016/j.ahj.2009.06.007
25 https://doi.org/10.1016/j.pbiomolbio.2008.10.006
26 https://doi.org/10.1016/j.pcad.2010.05.005
27 https://doi.org/10.1016/j.toxlet.2011.11.005
28 https://doi.org/10.1088/0957-4484/22/29/295104
29 https://doi.org/10.1093/annonc/mdq295
30 https://doi.org/10.1111/bcp.12082
31 https://doi.org/10.1128/aac.31.12.1897
32 https://doi.org/10.1152/ajpheart.00511.2012
33 https://doi.org/10.1177/009286150103500134
34 https://doi.org/10.1200/jco.2006.09.6925
35 https://doi.org/10.2147/jrlcr.s37138
36 schema:datePublished 2013-12
37 schema:datePublishedReg 2013-12-01
38 schema:description BACKGROUND: Cardiac toxicity is the foremost reason for drug discontinuation from development to clinical evaluation and post market surveillance [Fung 35:293-317, 2001; Piccini 158:317-326 2009]. The Food and Drug Administration (FDA) has rejected many potential pharmaceutical agents due to QT prolongation effects. Since drug development and FDA approval takes an enormous amount of time, money and effort with high failure rates, there is an increased focus on rescuing drugs that cause QT prolongation. If these otherwise safe and potent drugs were formulated in a unique way so as to mitigate the QT prolongation associated with them, these potent drugs may get FDA approval for clinical use. Rescuing these compounds not only benefit the patients who need them but also require much less time and money thus leading to faster clinical translation. In this study, we chose curcumin as our drug of choice since it has been shown to posses anti-tumor properties against various cancers with limited toxicity. The major limitations with this pharmacologically active drug are (a) its ability to prolong QT by inhibiting the hERG channel and (b) its low bioavailability. In our previous studies, we found that lipids have protective actions against hERG channel inhibition and therefore QT prolongation. RESULTS: Results of the manual patch clamp assay of HEK 293 cells clearly illustrated that our hybrid nanocurcumin formulation prevented the curcumin induced inhibition of hERG K+ channel at concentrations higher than the therapeutic concentrations of curcumin. Comparing the percent inhibition, the hybrid nanocurcumin limited inhibition to 24.8% at a high curcumin equivalent concentration of 18 μM. Liposomal curcumin could only decrease this inhibition upto 30% only at lower curcumin concentration of 6 μM but not at 18 μM concentration. CONCLUSIONS: Here we show a curcumin encapsulated lipopolymeric hybrid nanoparticle formulation which could protect against QT prolongation and also render increased bioavailability and stability thereby overcoming the limitations associated with curcumin.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree true
42 schema:isPartOf N70e561c38b724a008674b02e69186b31
43 Na7e8f2f7ad21437c92e21c6756ea6bfe
44 sg:journal.1031280
45 schema:name Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation
46 schema:pagination 40
47 schema:productId N00cba3cb60c94719b6719885495797e7
48 N499380a566944236a3f845ba86c9bd46
49 N7e606b85ca054930ae9dd2609047f272
50 N81b3355bf5994bacbd1fe61151cea62d
51 Nd163023e03194dea93c5a4fecddd5e83
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024171001
53 https://doi.org/10.1186/1477-3155-11-40
54 schema:sdDatePublished 2019-04-10T19:13
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N63f913fee40f416f9a6bc8643caf4926
57 schema:url http://link.springer.com/10.1186%2F1477-3155-11-40
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N00cba3cb60c94719b6719885495797e7 schema:name nlm_unique_id
62 schema:value 101152208
63 rdf:type schema:PropertyValue
64 N06ad92d30b414dacbb196e72d2b18e0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Ether-A-Go-Go Potassium Channels
66 rdf:type schema:DefinedTerm
67 N19c4e192cf0e49d59253614db0ec583b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Piperidines
69 rdf:type schema:DefinedTerm
70 N1f2d4d0dab0f47128de200cf41bab316 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Pyridines
72 rdf:type schema:DefinedTerm
73 N244b3ade743c46e89a06af5bea897514 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Patch-Clamp Techniques
75 rdf:type schema:DefinedTerm
76 N2f808023e7f9444192ca40cda7e1a6f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name ERG1 Potassium Channel
78 rdf:type schema:DefinedTerm
79 N32c8d3c9e6e74a2cac063e7664947957 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Anti-Arrhythmia Agents
81 rdf:type schema:DefinedTerm
82 N47712c3670f44ae585b3e7aecc074828 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Liposomes
84 rdf:type schema:DefinedTerm
85 N499380a566944236a3f845ba86c9bd46 schema:name readcube_id
86 schema:value 73273d75620d24914d1a8069d9b837502aeda4c0b78ce000d73081b7bb92663e
87 rdf:type schema:PropertyValue
88 N5fa6ba0fbc494508bd110ac4f1595839 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Curcumin
90 rdf:type schema:DefinedTerm
91 N632b924eb2f449d4a63ae7bf84bf2103 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Membrane Potentials
93 rdf:type schema:DefinedTerm
94 N63f913fee40f416f9a6bc8643caf4926 schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 N6597d5dee68d4efb9183c974ffc73ace rdf:first sg:person.01203736343.38
97 rdf:rest Nd7fb46613d4349e1bf89c07684b4cc6d
98 N70e561c38b724a008674b02e69186b31 schema:volumeNumber 11
99 rdf:type schema:PublicationVolume
100 N7e606b85ca054930ae9dd2609047f272 schema:name pubmed_id
101 schema:value 24330336
102 rdf:type schema:PropertyValue
103 N81b3355bf5994bacbd1fe61151cea62d schema:name dimensions_id
104 schema:value pub.1024171001
105 rdf:type schema:PropertyValue
106 N8b6cfd491ad34441b47c958d48eac9ea rdf:first sg:person.0702554625.45
107 rdf:rest N6597d5dee68d4efb9183c974ffc73ace
108 N8e5882437694465fbfe18d1c8f1f5048 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Humans
110 rdf:type schema:DefinedTerm
111 N91f7f175eb6b41f2b21d34412b5efb8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Delayed-Action Preparations
113 rdf:type schema:DefinedTerm
114 N96c374f0040346d1a703a2f8700434ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Ion Channel Gating
116 rdf:type schema:DefinedTerm
117 Na772e020e76e407890302fad2a9d5f63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Antineoplastic Agents, Phytogenic
119 rdf:type schema:DefinedTerm
120 Na7e8f2f7ad21437c92e21c6756ea6bfe schema:issueNumber 1
121 rdf:type schema:PublicationIssue
122 Nc10c75a15d5040348e5088dd2085477c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Translational Medical Research
124 rdf:type schema:DefinedTerm
125 Nc3319ffe951b4042a5af145e57cb5bbe schema:name SignPath Pharmaceuticals, Pennsylvania, USA
126 rdf:type schema:Organization
127 Nc645e0367b0f449990a4fea9ee58b74b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name HEK293 Cells
129 rdf:type schema:DefinedTerm
130 Nd163023e03194dea93c5a4fecddd5e83 schema:name doi
131 schema:value 10.1186/1477-3155-11-40
132 rdf:type schema:PropertyValue
133 Nd6a967aa430c4dbf9a7beb46a784aeac rdf:first sg:person.0747516710.37
134 rdf:rest rdf:nil
135 Nd7fb46613d4349e1bf89c07684b4cc6d rdf:first sg:person.0671324400.35
136 rdf:rest Nd6a967aa430c4dbf9a7beb46a784aeac
137 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
138 schema:name Medical and Health Sciences
139 rdf:type schema:DefinedTerm
140 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
141 schema:name Pharmacology and Pharmaceutical Sciences
142 rdf:type schema:DefinedTerm
143 sg:journal.1031280 schema:issn 1477-3155
144 schema:name Journal of Nanobiotechnology
145 rdf:type schema:Periodical
146 sg:person.01203736343.38 schema:affiliation https://www.grid.ac/institutes/grid.266871.c
147 schema:familyName Mukerjee
148 schema:givenName Anindita
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203736343.38
150 rdf:type schema:Person
151 sg:person.0671324400.35 schema:affiliation Nc3319ffe951b4042a5af145e57cb5bbe
152 schema:familyName Helson
153 schema:givenName Lawrence
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671324400.35
155 rdf:type schema:Person
156 sg:person.0702554625.45 schema:affiliation https://www.grid.ac/institutes/grid.266871.c
157 schema:familyName Ranjan
158 schema:givenName Amalendu P
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702554625.45
160 rdf:type schema:Person
161 sg:person.0747516710.37 schema:affiliation https://www.grid.ac/institutes/grid.266871.c
162 schema:familyName Vishwanatha
163 schema:givenName Jamboor K
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747516710.37
165 rdf:type schema:Person
166 sg:pub.10.1038/clpt.2010.286 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001165346
167 https://doi.org/10.1038/clpt.2010.286
168 rdf:type schema:CreativeWork
169 sg:pub.10.1186/1477-3155-10-38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014874253
170 https://doi.org/10.1186/1477-3155-10-38
171 rdf:type schema:CreativeWork
172 https://app.dimensions.ai/details/publication/pub.1077974252 schema:CreativeWork
173 https://doi.org/10.1002/prot.21400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034736497
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1016/0735-1097(95)00424-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029484792
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/j.ahj.2009.06.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000865834
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/j.pbiomolbio.2008.10.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036351969
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/j.pcad.2010.05.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034614849
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.toxlet.2011.11.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042447511
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1088/0957-4484/22/29/295104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004077122
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1093/annonc/mdq295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009767087
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1111/bcp.12082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037191447
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1128/aac.31.12.1897 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036116109
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1152/ajpheart.00511.2012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025168883
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1177/009286150103500134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026019679
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1200/jco.2006.09.6925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029954603
198 rdf:type schema:CreativeWork
199 https://doi.org/10.2147/jrlcr.s37138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046438963
200 rdf:type schema:CreativeWork
201 https://www.grid.ac/institutes/grid.266871.c schema:alternateName University of North Texas Health Science Center
202 schema:name Department of Molecular Biology & Immunology and Institute for Cancer Research, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, 76107, Fort Worth, Texas, USA
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...